Literature DB >> 15557761

Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.

Luiz Augusto Casulari1, Luciana A Naves, Paulo A Mello, Aldo Pereira Neto, Carla Papadia.   

Abstract

A woman affected by Cushing's disease underwent bilateral adrenalectomy followed by radiotherapy of the hypothalamic-pituitary area when she was 18 years old. Thereafter, she used hydrocortisone acetate replacement therapy (35.5 mg divided into two daily doses). At the age of 26 years, the patient exhibited the clinical signs of the Nelson's syndrome, i.e. skin and gingival hyperpigmentation accompanied by amenorrhea, and elevated ACTH plasma levels (2,850 pg/ml, normal range 15-80 pg/ml). The magnetic resonance imaging (MRI) analysis of the sellar region evidenced a pituitary macroadenoma, measuring 14 x 13 mm. The patient was initially treated with cyproheptadine hydrochloride (12 mg/day) for 18 months. There was a partial improvement of the symptoms, with a reduction of the ACTH plasma levels to 112 pg/ml, but without any modification of the tumor mass. Due to sleepiness and weight gain, the cyproheptadine treatment was interrupted and substituted by a cabergoline (0.5 mg twice a week) therapy. Soon after cabergoline was applied an improvement of the clinical symptoms and signs was observed such as a regression of the tumor mass and the normalization of the ACTH plasma titers (38 pg/ml). Later, cabergoline was substituted by bromocriptine (7.5 mg/day) and the plasma levels of ACTH increased again (247 pg/ml), and headache and cutaneous hyperpigmentation were recorded. When cabergoline was reintroduced there was a clinical improvement and normalization of ACTH plasma levels (64 pg/ml). The MRI analysis of the sella region demonstrated a complete remission of the pituitary adenoma. The results obtained show for the first time that a long-term treatment with cabergoline also brings about a complete remission of Nelson's syndrome in the presence of a pituitary macroadenoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557761     DOI: 10.1159/000082235

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  17 in total

1.  Medical combination therapies in Cushing's disease.

Authors:  Lucio Vilar; Luciana A Naves; Márcio C Machado; Marcello D Bronstein
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 2.  Bilateral adrenalectomy for Cushing's disease.

Authors:  Laurence Katznelson
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

4.  Disappearance of pituitary macro adenoma with combination of ketoconazole and cabergoline treatment: an unusual case of Cushing's syndrome with interesting findings.

Authors:  Asma Ahmed; Saira Furqan; Najmul Islam
Journal:  BMJ Case Rep       Date:  2012-07-03

Review 5.  Treatment of pituitary tumors: dopamine agonists.

Authors:  Gabriella Iván; Nikoletta Szigeti-Csúcs; Márk Oláh; György M Nagy; Miklós I Góth
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

6.  Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment.

Authors:  Ilana Shraga-Slutzky; Ilan Shimon; Ruth Weinshtein
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 7.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

8.  Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.

Authors:  Karen J Loechner; James T McLaughlin; Ali S Calikoglu
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-24

9.  Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.

Authors:  Lucio Vilar; Luciana A Naves; Monalisa F Azevedo; Maria Juliana Arruda; Carla M Arahata; Lidiane Moura E Silva; Rodrigo Agra; Lisete Pontes; Larissa Montenegro; José Luciano Albuquerque; Viviane Canadas
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

Review 10.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.